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Abstract
Background: Numerous studies in Chinese populations have evaluated the association between the A-6G and A-20C
polymorphisms in the promoter region of angiotensinogen gene and hypertension. However, the results remain conflicting.
We carried out a meta-analysis for these associations.
Methods and Results: Case–control studies in Chinese and English publications were identified by searching the MEDLINE,
EMBASE, CNKI, Wanfang, CBM, and VIP databases. The random-effects model was applied for dichotomous outcomes to
combine the results of the individual studies. We finally selected 24 studies containing 5932 hypertensive patients and 5231
normotensive controls. Overall, we found significant association between the A-6G polymorphism and the decreased risk of
hypertension in the dominant genetic model (AA+AG vs. GG: P=0.001, OR=0.71, 95%CI 0.57–0.87, Pheterogeneity=0.96). The
A-20C polymorphism was significantly associated with the increased risk for hypertension in the allele comparison (C vs. A:
P=0.03, OR=1.14, 95%CI 1.02–1.27, Pheterogeneity=0.92) and recessive genetic model (CC vs. CA+AA: P=0.005, OR=1.71,
95%CI 1.18–2.48, Pheterogeneity=0.99). In the subgroup analysis by ethnicity, significant association was also found among
Han Chinese for both A-6G and A-20C polymorphisms. A borderline significantly decreased risk of hypertension between A-
6G and Chinese Mongolian was seen in the allele comparison (A vs. G: P=0.05, OR=0.79, 95%CI 0.62–1.00,
Pheterogeneity=0.84).
Conclusion: Our meta-analysis indicated significant association between angiotensinogen promoter polymorphisms and
hypertension in the Chinese populations, especially in Han Chinese.
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Introduction
Essential hypertension (EH), the major section (over 95%) of
hypertension, represents a serious health problem all over the
world. In China, hypertension affects more than 18.8% of the
adult population, and a total of 170 million people suffer from this
disease [1]. Hypertension has a multi-factorial origin arising from
an interaction between susceptibility genes and environmental
factors [2]. It is noteworthy that about 20% to 60% of the inter-
individual variation of blood pressure (BP) is determined by
heritable factors [3]. As a consequence, many potential genes
involved in blood pressure regulation have been screened and
recognized as candidates for hypertension.
The renin-angiotensin-aldosterone system (RAAS) plays a
crucial role in the maintenance of BP [4]. Among the system,
the angiotensinogen (AGT) is a liver protein that interplays with
renin to produce angiotensin I, the prohormone of angiotensin II,
which is the major effector molecule of RAAS. The human AGT
gene is located on chromosome 1 (1q42–q43) and contains 5 exons
[5]. Many variants in the AGT gene can modify the plasma AGT
concentration that is directly linked with arterial blood pressure
[6]. At present, we paid particular attention to the rs5051 (A-6G)
and rs5050 (A-20C) single nucleotide polymorphisms (SNPs) in the
promoter region, which both were reported to influence AGT
transcriptional activity and then plasma AGT [6]. Haplotype
analysis has revealed that the two SNPs, A-6G and A-20C, were in
strong linkage disequilibrium [7].
In a 2008 meta-analysis by Pereira et al. [8], the relationship
between hypertension and the A-6G and A-20C polymorphisms
has been evaluated in European Caucasian subjects. However, no
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conducted in Chinese populations so far. The genetic background
difference between the two ethnic groups may lead to different
conclusions. In addition, the published results of Chinese case-
control studies for both polymorphisms remained unsettled. Some
studies implied that the A-6G polymorphism [9–12] as well as A-
20C polymorphism [13] in the AGT gene were associated with the
increased or even reduced risk of EH in Chinese, whereas most
studies [14–24] still provided equivocal or largely negative
evidence for this relationship. Taken together, we decided to
perform a carefully designed meta-analysis from all eligible case-
control studies, in order to clarify the role of the A-6G and A-20C
polymorphisms in hypertension among the Chinese populations.
Materials and Methods
Identification and eligibility of relevant studies
To search for all the studies that examined the association of the
A-6G and A-20C polymorphisms with hypertension in Chinese,
we conducted a computerized literature search of the PubMed,
EMBASE, CNKI (China Nation Knowledge Infrastructure
Platform), Wanfang, CBM (China Biological Medicine Database)
and VIP databases (up to May 2011), using the following keywords
and subject terms: ‘AGT or Angiotensinogen’, ‘polymorphism’,
‘hypertension’ and ‘Chinese or China or Taiwanese or Taiwan’.
We only included studies published in Chinese or in English.
References of retrieved articles were also screened. When a report
overlapped with another publication, to prevent data duplication,
only the more detailed one was kept. If an article reported results
on different ethnic sub-populations, each sub-population was
treated as separate study in our meta-analysis. We used the
following inclusion criteria for a study to be included in the meta-
analysis: (a) studies investigating the association of the A-6G or A-
20C polymorphisms with hypertension in Chinese individuals, (b)
use of an unrelated case–control design (family-based study design
with linkage considerations was excluded), (c) available genotype
frequency, (d) the genotype distribution of the control population
must be in Hardy–Weinberg equilibrium (HWE) and (e)
hypertension defined as systolic blood pressure (SBP)$140 mmHg
and/or diastolic blood pressure (DBP)$90 mmHg and/or treat-
ment with anti-hypertensive medication. If the genotype frequency
was not reported, we contacted the original authors by e-mail in
order to obtain the missing data.
Data extraction
Two authors (W. Gu and J. Liu) independently reviewed and
extracted the data needed. Disagreements were resolved through
discussion among the authors to achieve a consensus. The
following information was abstracted from each study: first author,
year of publication, racial background and resident region of study
population, diagnostic criteria, matching, source of samples,
genotype detecting method of each study, number of cases and
controls, distribution of genotypes and alleles in both case and
control groups.
Statistical analysis
Odds ratios (OR) corresponding to 95% confidence interval (CI)
was applied to measure the strength of the association of A-6G and
A-20C with hypertension as case–control studies were used, and
OR was calculated according to the method of Woolf [25]. We
examined the association between allele A of A-6G and
hypertension (A vs. G), the dominant genetic model (AA+AG vs.
GG), and the recessive genetic model (AA vs. AG+GG). The same
method was applied to analyze the A-20C polymorphism. In our
study, only the random-effects model using the DerSimonian and
Laird’s method was employed to bring the individual effect-size
estimates together in Review-Manager 5.0.25 software [26]. We
then performed a chi-square-based Q statistic test to assess the
between-study heterogeneity [27]. Heterogeneity was considered
significant for P,0.10 because of the low power of the statistic.
The inconsistency index I
2 was also calculated to evaluate the
variation which was caused by heterogeneity rather than by
chance, and higher values of the index indicate the existence of
heterogeneity [28]. The significance of the pooled OR was
determined by the Z test and a P value of ,0.05 was considered
significant. For each genetic comparison, subgroup analysis
according to racial descent was considered for Han Chinese and
non-Han Chinese minorities to estimate ethnic-specific OR. In
addition, subgroup analysis according to gender was also carried
out. Each subgroup had at least two independent studies.
When unexpected heterogeneity was present, sensitivity analysis
was performed to examine specific sensitivity of the findings. This
analysis was conducted by examining and recalculating the pooled
association sizes and joint values of P in homogeneous subgroups,
as well as after excluding studies one by one.
Publication bias was investigated by funnel plot, in which the
standard error of the log (OR) of each study was plotted against its
OR. An asymmetric plot suggested possible publication bias.
Funnel-plot asymmetry was assessed by the method of Egger’s
linear regression test [29]. We performed a t-test to determine the
significance of the intercept, and a P-value of ,0.05 was
considered significant. HWE was tested by the chi-square-test
for goodness of fit based on a web program (http://ihg.gsf.de/cgi-
bin/hw/hwa1.pl). All statistical analyses were performed using
ReviewManager 5.0.25 (Oxford, England) and the software Stata
version 10.0 (Stata Corporation, College Station, Texas, USA). All
P-values were two-sided.
Results
Selection of studies
After literature search and selection applying our inclusion
criteria, we identified a total of 27 relevant articles (40 studies) [7–
24,30–38]. Among the 40 eligible studies, seven studies [13,23,30–
34] were excluded because they shared the same or overlapping
data with others. Moreover, eight studies [13–14,22,24,32,35–37]
with control groups deviating from HWE were deleted. Finally, 15
studies [7,9–12,14–21,38] containing 3442 hypertensive patients
and 3058 controls for A-6G, as well as 9 studies [7,11,15,17,20–24]
containing2490 hypertensive patients and 2173 controls for A-20C,
were collected as being appropriate for the meta-analysis (Figure 1).
Thereof,Geetal.[16],Wangetal.[18] Yueetal.[21] and Liu etal.
[38], were four unpublished theses acquired from medical doctorate
dissertation database, which was one public sub-database shared by
CNKI and Wanfang databases. One paper by Liu et al. [12]
provided data on subjects of two Chinese minorities: Tibetan and
Yi.Thus,thetwo minoritiesweretreatedasseparate studies.Forthe
Yi population, the samples (both cases and controls) were selected
only from male individuals. The characteristics of the included
studies were summarized in Table 1. Genotype distributions of the
control population met HWE for all qualified studies (P.0.05). The
flowchartsummarizingtheprocessofstudyselectionand reasonsfor
exclusion was presented in Figure 1.
Association between the AGT A-6G polymorphism and
hypertension
The distribution of AGT A-6G genotypes and alleles in the
individual studies was listed in Table 2. The pooled overall
AGT Polymorphisms and Hypertension
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in hypertensive cases and 76.60% in normotensive controls. The
main results of the meta-analysis about A-6G and the heteroge-
neity test were presented in Table S1. For all subjects, in the allele
comparison and recessive genetic model, there were no significant
association between the A-6G polymorphism and hypertension (A
vs. G: P=0.08, OR=0.9, 95%CI 0.8–1.01, Pheterogeneity=0.09,
I
2=35%. AA vs. AG+GG: P=0.4, OR=0.93, 95%CI 0.8–1.09,
Pheterogeneity=0.04, I
2=43%) (Table S1). However, we detected
significantly reduced risk of hypertension in the dominant genetic
model (AA+AG vs. GG: P=0.001, OR=0.71, 95%CI 0.57–0.87,
Pheterogeneity=0.96, I
2=0) (Figure 2).
In the subgroup analysis by ethnicity, studies were categorized
into three groups: Han Chinese, Tibetan and Mongolian. The
number of these subpopulations was as follows: six studies
involved Han Chinese subjects (2295 cases and 1884 controls),
two studies involved Chinese Mongolian (350 cases and 366
controls) and two studies involved Chinese Tibetan (259 cases
and 325 controls). The -6A allele had a much higher
representation in cases and controls of Han Chinese (76.54%
and 77.92%, respectively) than that of Tibetan (64.87 and
69.84%, respectively) and of Mongolian (71.86 and 76.5%,
respectively). In Han Chinese population, significant association
between the A-6G polymorphism and the decreased risk for
hypertension was observed in the dominant genetic model
(AA+AG vs. GG: P=0.005, OR=0.66, 95%CI 0.50–0.88,
Pheterogeneity=0.64, I
2=0)(Table S1). In the allele comparison
and recessive genetic model, no evidence of association was found
(Table S1). For the subgroups of non-Han Chinese minorities, we
found no significant association in any genetic models in the
population of Tibetan (Table S1). For Mongolian, a borderline
decreased risk of hypertension was seen for A allele carriers
compared with G allele carriers (A vs. G: P=0.05, OR=0.79,
95%CI 0.62–1.00, Pheterogeneity=0.84, I
2=31%) (Table S1).
There was no significant association found in other genetic
models conducted using Mongolian (Table S1).
Considering the fact that the sex discrepancy might bias the
overall association, a further subgroup analysis was conducted
according to gender. As reflected in Table 3, four studies (3
articles) provided data for males and females, respectively.
Accordingly, a total of 269 hypertension patients and 316 controls
for males, as well as 296 hypertension patients and 349 controls for
females, were investigated. In male subjects, the lack of significant
association was found between A-6G and hypertension in all
Figure 1. The flowchart of selection of studies and specific reasons for exclusion from the meta-analysis.
doi:10.1371/journal.pone.0029489.g001
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Pheterogeneity=0.24, I
2=29%) (Figure 3a). However, in female
subjects, the A-6G polymorphism displayed significantly reduced
risk for hypertension in the allele comparison (A vs. G: P=0.01,
OR=0.73, 95%CI 0.57–0.93, Pheterogeneity=0.40, I
2=0%)
(Figure 3b) and recessive genetic model (AA vs. AG+GG:
P=0.02, OR=0.69, 95%CI 0.50–0.95, Pheterogeneity=0.49,
I
2=0%).
Table 1. Detailed characteristics of eligible studies considered in the meta-analysis.
First author Year Ethnicity Region
Single-nucleotide
polymorphism Diagnostic criteria Matching Source Method
Ge [16] 2000 Tibetan Tibet A-6G SBP$140, DBP$90 Yes P-B PCR-RFLP
Hu [14] 2007 Mongolian Inner Mongolian A-6G SBP$140, DBP$90 Yes P-B Sequencing technique
Jiang [17] 2009 Han Jiangsu A-6G, A-20C SBP$140, DBP$90 Yes P-B TaqMan - PCR
Kong [15] 2002 Han Henan A-6G, A-20C SBP$160, DBP$95 Yes H-B PCR-RFLP
Liu [38] 2002 Han Shanghai A-6G SBP$140, DBP$90 No H-B Sequencing technique
Li [22] 2004 Kazakh Xinjiang A-20C SBP$140, DBP$90 Yes
1 P-B PCR-SSCP
Liu [12] 2001 Tibetan Tibet A-6G SBP.140, DBP.90 Yes P-B PCR-RFLP
Liu [12] 2001 Yi Sichuan A-6G SBP.140, DBP.90 Yes P-B PCR-RFLP
Qi [7] 2008 Han Beijing A-6G, A-20C SBP$140, DBP$90 Yes
1 P-B PCR-RFLP
Wang [9] 2002 Amis Taiwan A-6G SBP$140, DBP$90 Yes H-B Sequencing technique
Wang [18] 2003 Kazakh Xinjiang A-6G SBP$160, DBP$95 Yes P-B MS-PCR
Wang [11] 2007 Li Hainan A-6G, A-20C SBP$140, DBP$90 Yes H-B Sequencing technique
Wu [10] 2004 Han Taiwan A-6G SBP$140, DBP$90 Yes
1 H-B Sequencing technique
Yang [23] 2000 Tibetan Tibet A-20C SBP$140, DBP$90 Yes P-B PCR-RFLP
Yao [19] 2010 Bai Yunnan A-6G SBP$140, DBP$90 No H-B PCR-RFLP
Ying [20] 2010 Mongolian Inner Mongolian A-6G, A-20C SBP$140, DBP$90 No P-B PCR-RFLP
Yue [21] 2008 Han Hebei A-6G, A-20C SBP$140, DBP$90 Yes2 P-B PCR-RFLP
Liu [24] 2004 Han Shanghai A-20C SBP.140, DBP.90 No H-B Sequencing technique
Abbreviations: SBP, systolic blood pressure (mmHg); DBP, diastolic blood pressure (mmHg); P-B, population-based study; H-B, hospital-based study; PCR-RFLP,
polymerase chain reaction and restriction fragment length polymorphism; PCR-SSCP, polymerase chain reaction and single strand conformation polymorphism; MS-
PCR, mutagenically separated polymerase chain reaction; Yes, age- and gender- matched, Yes
1, gender-matched, Yes
2, age-matched.
doi:10.1371/journal.pone.0029489.t001
Table 2. Sample size, the distribution of A-6G genotypes and allele frequencies, and P-values of HWE.
Sample size AA(genotype) AG(genotype) GG(genotype) A allele frequency (%) HWE(P* value)
First author Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Controls
Ge [16] 96 112 36 49 50 55 10 8 63.54 68.30 0.1558
Hu [14] 107 108 53 59 35 37 19 12 65.89 71.76 0.1078
Jiang [17] 220 235 136 169 74 62 10 4 78.64 85.11 0.5325
Kong [15] 324 187 200 104 112 77 12 6 79.01 76.20 0.0641
Liu(Han) [38] 97 90 65 59 27 27 5 4 80.93 80.56 0.6878
Liu(Tibetan) [12] 163 213 64 102 86 97 13 14 65.64 70.66 0.2927
Liu(Yi) [12] 63 82 47 52 15 27 1 3 86.51 79.88 0.8259
Qi [7] 1122 965 671 608 378 313 73 44 76.65 79.22 0.6470
Wang(Amis) [9] 107 96 89 65 17 30 1 1 91.12 83.33 0.2207
Wang(Kazakh) [18] 201 151 77 52 81 71 43 28 58.46 57.95 0.6550
Wang(Li) [11] 100 100 83 89 15 10 2 1 90.50 94.00 0.2565
Wu [10] 459 325 316 229 121 90 22 6 82.03 84.31 0.4010
Yao [19] 67 54 33 30 31 21 3 3 73.49 75.00 0.7855
Ying [20] 243 258 138 161 86 83 19 14 74.49 78.49 0.4473
Yue [21] 73 82 3 1 19 27 51 54 80.77 82.32 0.2354
Abbreviations: HWE, Hardy–Weinberg equilibrium.
*The P-value of HWE determined by the x
2 test.
doi:10.1371/journal.pone.0029489.t002
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hypertension
The distribution of AGT A-20C genotypes and alleles in the
individual studies was showed in Table 4. The overall prevalence
of the -20C allele in the Chinese populations was 16.43% in cases
and 14.98% in controls. The main results of the meta-analysis
about A-20C and the heterogeneity test were presented in Table
S1. Overall, the significant increased risk of hypertension could be
found in the allele comparison (C vs. A: P=0.03, OR=1.14,
95%CI 1.02–1.27, Pheterogeneity=0.92, I
2=0) (Figure 4a) and
recessive genetic model (CC vs. CA+AA: P=0.005, OR=1.71,
95%CI 1.18–2.48, Pheterogeneity=0.99, I
2=0) (Figure 4b). There
was no significant association found in the dominant genetic model
(CC+CA vs. AA: P=0.14, OR=1.10, 95%CI 0.97–1.25,
Pheterogeneity=0.83, I
2=0) (Table S1).
Due to the limited studies of non-Han Chinese minorities, the
subgroup analysis by ethnicity was only performed for Han
Chinese. Specifically, there were five studies dealing with Han
Chinese (1919 cases and 1661 controls), and only one study
considered Kazakh, Li, Tibetan and Mongolian populations. In
the Han population, we found significantly elevated risk of
hypertension with the A-20C polymorphism in the allele
comparison (C vs. A: P=0.02, OR=1.17, 95%CI 1.02–1.33,
Pheterogeneity=0.67, I
2=0) and recessive genetic model (CC vs.
CA+AA: P=0.04, OR=1.58, 95%CI 1.02–2.45, Pheterogeneity=
1.00, I
2=0) (Table S1). No positive association was obtained in the
dominant genetic model (Table S1). Finally, because only one
article [20] provided data for males and females, respectively, we
could not perform an additional subgroup analysis based on
gender.
Sensitivity analysis
Significant between-study heterogeneity only existed among all
studies in the meta-analysis of the A-6G polymorphism. Sensitivity
analyses were conducted by sequentially removing a single study
each time to find out the origin of heterogeneity. As a result, the
heterogeneity no longer existed for the A-6G polymorphism when
four studies were excluded (Liu (Yi) et al. [12]: A vs. G,
Pheterogeneity=0.15; Kong et al. [15]: A vs. G, Pheterogeneity=0.16;
Jiang et al. [17]: A vs. G, Pheterogeneity=0.16; Wang (Amis) et al.
Figure 2. Meta-analysis for the overall association between the A-6G polymorphism and hypertension under the dominant genetic
model. Figure 2 shows that the -6A allele carrier (AA+AG) can reduce the risk of hypertension compared to the homozygous GG genotype carriers.
doi:10.1371/journal.pone.0029489.g002
Table 3. The characteristics of all included studies for the A-6G polymorphism in the sex-specific subgroup analysis.
Genotype(Number, M/F) Blood pressure
First author Ethnicity Status Number, M/F AA AG GG Age, year BMI, kg/m
2 SBP, mmHg DBP, mmHg
Ge [16] Tibetan Cases 37/59 16/20 18/32 3/7 49.53611.4 23.3463.99 159.74623.15 105.96610.83
Controls 48/64 17/32 26/29 5/3 47.98612.07 21.5463.11 116.38616.66 78.2169.94
Liu(Tibetan) [12] Tibetan Cases 71/92 30/34 38/48 3/10 48612 2464 164620 105612
Controls 110/103 52/50 48/49 10/4 46610 2263 117614 7869
Liu(Yi) [12] Yi Cases 63/0 47/0 15/0 1/0 51612 2564 158630 103616
Controls 82/0 52/0 27/0 3/0 49662 1 63 112687 3 66
Ying [20] Mongolian Cases 98/145 52/86 35/51 11/8 53.5611.3 23.264.1 159.4624.2 98.3611.3
Controls 76/182 45/116 27/56 4/10 50.369.5 22.163.2 119.6610.8 78.166.3
Abbreviations: M/F, males/females; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Values, mean6s.d.
doi:10.1371/journal.pone.0029489.t003
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0.23). In addition, our analysis showed that the corresponding
pooled ORs were materially altered with the sequential removal of
these four studies (data not shown). The findings revealed that
these independent studies might be the main cause of heteroge-
neity across all subjects.
Publication bias
The Egger’s test and Begg’s funnel plot were applied for allele
comparison to asses the publication bias of the literatures. As
indicated by the Egger’s test and funnel plot, there was no
publication bias for the A-6G polymorphism (t=0.98, P=0.347
for A vs. G) (Figure 5a), and a possibility of publication bias for the
A-20C polymorphism (t=23.88, P=0.006 for C vs. A)
(Figure 5b).
Discussion
The literature examining the relationship between the A-6G
and A-20C polymorphisms and hypertension in the Chinese
populations abounds in small studies reporting controversial
findings. No clear consensus has yet been reached. Therefore,
we restricted our research to Chinese populations and did a meta-
analysis with 24 studies totaling 5932 hypertensive patients and
5231 normotensive controls to form a more precise estimation of
their association. To our knowledge, this was one of the largest
meta-analysis to date investigating the association of angiotensin-
ogen promoter polymorphisms with hypertension in Chinese. In
the current study, we found that the A allele of the A-6G
polymorphism was associated with a significant decrease in the risk
of hypertension in all subject, and the C allele of A-20C could
Figure 3. Meta-analysis for the association between the A-6G polymorphism and hypertension under allele comparison (A vs. G) in
the subgroup by sex. Figure 3a shows that the A-6G polymorphism is not associated with hypertension in men. Figure 3b shows that the -6 A
allele carrier can reduce the risk of hypertension in women compared to the -6G allele carrier.
doi:10.1371/journal.pone.0029489.g003
Table 4. Sample size, the distribution of A-20C genotypes and allele frequencies, and P-values of HWE.
Sample size CC(genotype) CA(genotype) AA(genotype)
C allele
Frequency(%)
HWE(P*
value)
First author Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Controls
Jiang [17] 208 234 6 4 54 63 148 167 15.87 15.17 0.4815
Kong [15] 326 195 8 3 72 42 246 150 13.50 12.31 0.9756
Li [22] 125 74 6 1 32 24 87 49 17.60 17.57 0.3028
Liu [24] 185 185 4 2 62 55 119 128 18.92 15.95 0.1380
Qi [7] 1122 965 39 22 294 220 789 723 16.58 13.68 0.2823
Wang [11] 100 100 7 3 36 39 57 58 25.00 22.50 0.2367
Yang [23] 103 80 0 0 17 14 86 66 8.25 8.75 0.3910
Ying [20] 243 258 13 8 64 76 166 174 18.52 17.83 0.9317
Yue [21] 78 82 1 1 19 24 58 57 13.46 15.85 0.3798
Abbreviations: HWE, Hardy–Weinberg equilibrium.
*The P-value of HWE determined by the x
2 test.
doi:10.1371/journal.pone.0029489.t004
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should be treated with caution as the P values obtained were
reported without correction for multiple testing.
In 1997, Inoue et al. [39] were the first to provide direct
evidence for increased transcriptional activity of the -6A variant as
compared with the -6G variant in the AGT promoter in a
hepatocyte cell line. Since then, much effort has been made to
pursue the possible association of the A-6G polymorphism with
hypertension. Hegele RA et al. [40] observed that the presence of
the AGT -6A variant tended to be associated with higher systolic
BP in Canadian Oji-Cree. This positive result was partly
confirmed by Ishigami T et al. [41] who studied on Japanese
population. A more recent research by Jain S et al. [42] showed
that transgenic mice containing -6A haplotype have increased
plasma AGT level and increased blood pressure as compared to -
6G haplotype, and also reported higher expression of AGT
mRNA in Caucasian hypertensive patients carrying the same
allele. Moreover, Pereira TV’s meta-analysis [8] that came out in
2007 found that A-6G have a higher yet nonsignificant risk for
hypertension in Asian populations. The Asian participants
included in the analysis were not all from Chinese population,
which meant genetic background between this article and our
study was different. Nevertheless, these previous findings were
inconsistent with the result of our meta-analysis, which was very
interesting and exhibited a protective effect on hypertension in the
Chinese populations. There were many possible explanations that
could be put forward to account for the inconsistency, and ethnic
specificity as well as population structure might be the most
important potential confounding factors. An obvious supporter
was a Chinese case-control study by Liu et al. [12] also generating
a protective effect of the A-6G variant on hypertension. It was
necessary to perform a meta-analysis in a genetically well-defined
population.
Regarding the A-20C polymorphism, a report by Zhao et al.
[43] showed that the -20C allele enhanced basal promoter activity
on transient transfection in human hepatoma cells (HepG2) as
compared with the -20A allele. In human subjects, DR Velez et al.
[44] found that this polymorphism seemed to be involved in
hypertension in white women. A Chinese case-control article [13]
also displayed that the -20C variant could apparently increase the
risk of hypertension in the Taiwanese population. Then the results
of a 2008 meta-analysis [8] and our meta-analysis verified that the
A-20C polymorphism might be major genetic predisposing factor
for hypertension in the Chinese populations. Furthermore, with a
tight linkage disequilibrium (LD) between the M235T and A-20C
polymorphisms, our results about the relationship between A-20C
and EH are consistent with previous results by Ji et al. [45] in
2010, which reported that the M235T variant increases the risk of
essential hypertension in the Chinese populations (OR=1.54,
95%CI 1.16–2.03, P=0.002). An interaction between the A-6G
and A–20C variants was biologically plausible [32,46] because
these 2 variants were located in 2 distinct regulatory elements of
the core promoter in AGT gene. Subsequently, this interaction
between them might affect the transcription of the gene and/or
the stability of the resulting mRNA, and in turn play an important
role in the pathogenesis of hypertension. Niu et al. [32] observed
Figure 4. Meta-analysis for the overall association between the A-20C polymorphism and hypertension under various genetic
contrasts. Figure 4a shows that the C allele carrier can increase the risk of hypertension compared to the A allele carrier. Figure 4b shows that the
homozygous CC genotype carriers can increase the risk of hypertension compared to the A allele carrier (CA+AA).
doi:10.1371/journal.pone.0029489.g004
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with hypertension, which might be attributed to a strong
synergistic effect of these two polymorphisms.
China is a huge multi-ethnic country with 56 identified ethnic
groups. Among these groups, Han Chinese is the largest ethnic
group, making up over 93% of the total population [47]. In the
subgroup analysis, we divided studies into two subgroups: Han
Chinese and non-Han Chinese minorities. Significant association
was identified in Han Chinese for both A-6G and A-20C
polymorphisms, which were in accordance with the results in the
overall population. For non-Han Chinese minorities, owing to the
limited studies and population numbers, only a marginal
significant association between A-6G and hypertension was seen
in Chinese Mongolian. More studies based on larger population
are required to reach more obvious conclusion in different
minorities. In another subgroup analysis by gender, the signifi-
cantly decreased risk of hypertension was associated with the A-6G
polymorphism in Chinese women, but not in Chinese men.
However, in the view of the relatively small sample size, the
conclusion in this sex-specific analysis might be unreliable and
must be considered cautiously. Furthermore, no extra subgroup
analysis according to gender was undertaken for the A-20C
polymorphism because the eligible studies were scarce in number.
In the sensitivity analysis, four studies (Wang (Amis) et al. [9], Liu
Figure 5. Begg’s funnel plot analysis to detect publication bias. Figure 5a shows the funnel plot for allele comparison (A vs. G) of the A-6G
polymorphism. Figure 5b shows the funnel plot for allele comparison (C vs. A) of the A-20C polymorphism.
doi:10.1371/journal.pone.0029489.g005
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considered as the origin of the heterogeneity. When these articles
were deleted, significant association could be found.
The positive findings about A-20C should be interpreted in light
of the fact that publication bias was detected. The statistical test
and funnel plot inspection in the meta- analysis have indicated the
potential for such bias. Publication bias is a relatively common
phenomenon in clinical literature [48–50], perhaps because
positive results have a better chance of being accepted for
publication than small studies with non-significant or negative
findings. Therefore, conclusions based on these published work
might be misleading [51]. In the analysis of the A-20C
polymorphism, we conducted a comprehensive search of the
published literature and thought it unlikely that many important
papers would have been overlooked, but despite this effort, there
was still a possibility of publication bias. Thus, the positive findings
for A-20C have to be regarded as preliminary.
Several limitations of our meta-analysis need to be noted. First,
because of a small number of available studies, we failed to
perform additional subgroup analysis in other minority popula-
tions (such as Bai), and by gender for the A-20C polymorphism.
Second, publication bias was present, and might distort the final
conclusion. Third, due to the lack of original data, an evaluation of
potential interactions such as gene-gene or gene-environment was
not considered in this meta-analysis, which might confound our
results.
In conclusion, our meta-analysis suggested significant associa-
tion between the A-6G and A-20C polymorphisms and hyperten-
sion in the Chinese populations, particularly in Han Chinese.
More large–scale studies, and especially studies stratified for
different minorities and different sexes, should be performed to
further elucidate the association between the A-6G and A-20C
polymorphisms and hypertension in the Chinese populations.
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